Heron Therapeutics (HRTX) Amortization of Deferred Charges (2021 - 2025)
Heron Therapeutics (HRTX) reported Amortization of Deferred Charges of -$35000.0 for Q4 2025, down 166.04% on a YoY basis from $53000.0 in Q4 2024, and down 135.0% quarter-over-quarter from $100000.0 in Q2 2025.
Heron Therapeutics (HRTX) Amortization of Deferred Charges (2021 - 2025) Analysis & Trends
Heron Therapeutics has reported Amortization of Deferred Charges for 5 years, with the latest figure at -$35000.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges fell 166.04% year-over-year to -$35000.0; the trailing twelve-month figure through Dec 2025 stood at $118000.0 (down 61.31% YoY), and the FY2025 full-year result was $73000.0, down 65.24% from the prior year.
- Amortization of Deferred Charges for Q4 2025 stood at -$35000.0, down from $100000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $100000.0 in Q3 2023, with the low at -$35000.0 in Q4 2025.
- Historically, Amortization of Deferred Charges has averaged $55333.3 across 5 years, with a median of $51000.0 in 2022.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges soared 163.16% — and 2025, when it slumped 166.04%.
- Heron Therapeutics' Amortization of Deferred Charges stood at $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then grew by 2.0% to $51000.0 in 2023, then increased by 3.92% to $53000.0 in 2024, then tumbled by 166.04% to -$35000.0 in 2025.
- The last three Amortization of Deferred Charges figures came in at -$35000.0 (Q4 2025), $100000.0 (Q2 2025), and $53000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Heron Therapeutics | 77.43 Mn | 47.47 Mn | 24.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -35,000.00 |
| Dec 31, 2025 | -35,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 53,000.00 |
| Mar 31, 2025 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 52,000.00 |
| Mar 31, 2024 | 52,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Jun 30, 2023 | 51,000.00 |